The Food and Drug Administration (FDA) approves a new tablet formulation of Abbott's HIV protease inhibitor Kaletra (lopinavir/ritonavir), which will allow adult patients to take fewer pills with or without food as part of their treatment regimen.

Additionally, there will be no refrigeration requirements for the tablets. These benefits were not available with the old Kaletra capsules. The FDA says the standard daily doses of new Kaletra tablets and capsules provide similar drug levels in the blood

Abbott, a leader in HIV/AIDS research since the early days of the deadly epidemic, announces it has received U.S. Food and Drug Administration (FDA) approval for a new tablet formulation of its HIV protease inhibitor (PI) Kaletra.

The drug will allow adult patients to take fewer pills with or without food as part of their treatment. In contrats to the old drug, there will be no refrigeration requirements for the tablets